Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
Public ClinicalTrials.gov record NCT01167881. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomised, Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 10773 Compared to Glimepiride Administered Orally During 104 Weeks With a 104 Week Extension Period in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Metformin Treatment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a pivotal phase III study, mandatory to seek approval by regulatory authorities for BI 10773 as an anti-diabetic agent compared to an active comparator in patients with type 2 diabetes mellitus and insufficient glycaemic control.
Study identification
- NCT ID
- NCT01167881
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,549 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2010 (Type not available)
- Primary completion
- Aug 2013 (Actual)
- Completion
- Aug 2015 (Actual)
- Last update posted
- Sep 2, 2016
2010 – 2015
United States locations
- U.S. sites
- 25
- U.S. states
- 15
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1245.28.10005 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 1245.28.10012 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 1245.28.10016 Boehringer Ingelheim Investigational Site | Hot Springs | Arkansas | — | — |
| 1245.28.10003 Boehringer Ingelheim Investigational Site | Sacramento | California | — | — |
| 1245.28.10021 Boehringer Ingelheim Investigational Site | West Hills | California | — | — |
| 1245.28.10009 Boehringer Ingelheim Investigational Site | Bradednton | Florida | — | — |
| 1245.28.10015 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 1245.28.10033 Boehringer Ingelheim Investigational Site | Blue Ridge | Georgia | — | — |
| 1245.28.10026 Boehringer Ingelheim Investigational Site | Boise | Idaho | — | — |
| 1245.28.10007 Boehringer Ingelheim Investigational Site | Omaha | Nebraska | — | — |
| 1245.28.10027 Boehringer Ingelheim Investigational Site | Henderson | Nevada | — | — |
| 1245.28.10014 Boehringer Ingelheim Investigational Site | Rochester | New York | — | — |
| 1245.28.10006 Boehringer Ingelheim Investigational Site | Shelby | North Carolina | — | — |
| 1245.28.10011 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1245.28.10019 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1245.28.10004 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 1245.28.10008 Boehringer Ingelheim Investigational Site | Perrysburg | Ohio | — | — |
| 1245.28.10020 Boehringer Ingelheim Investigational Site | Medford | Oregon | — | — |
| 1245.28.10017 Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| 1245.28.10031 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1245.28.10032 Boehringer Ingelheim Investigational Site | Longview | Texas | — | — |
| 1245.28.10022 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1245.28.10030 Boehringer Ingelheim Investigational Site | Draper | Utah | — | — |
| 1245.28.10023 Boehringer Ingelheim Investigational Site | Salt Lake City | Utah | — | — |
| 1245.28.10013 Boehringer Ingelheim Investigational Site | Kenosha | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 157 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01167881, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 2, 2016 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01167881 live on ClinicalTrials.gov.